Skip to content

Exploring the correlation among metabolism and transport gene polymorphism of methotrexate and its treatment toxicity

Exploring the correlation among metabolism and transport gene polymorphism of methotrexate and its treatment toxicity

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200065150
Enrollment
Unknown
Registered
2022-10-29
Start date
2022-11-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteosarcoma

Interventions

osteosarcoma group:None

Sponsors

The Second Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.hospitalized patients diagnosed as acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma, osteosarcoma; 2.the age of patients from 5 to 70; 3.the chemotherapy regimen is included high-dose MTX;4.the whole chemotherapy regimen with HD-MTX is under therapeutic drug monitoring; 5.the liver and kidney functions are normal before chemotherapy, and the hepatitis B surface antigen is negative.

Exclusion criteria

Exclusion criteria: 1.pregnant women and/or patients without high-dose MTX; 2.patients with severe liver diseases such as viral hepatitis, liver cirrhosis, drug-induced liver damage, and liver cancer upon admission; 3.patients who stopped HDMTX treatment due to severe adverse reactions or other reasons; 4.the case of patient is incomplete or none in the medical record system; 5.drinking and/or smoking.

Design outcomes

Primary

MeasureTime frame
Genetic mutations;Liver function parameters;Blood routine examination;Plasma concentration;

Countries

China

Contacts

Public ContactCai Hualin

The Second Xiangya Hospital, Central South University

hualincai@csu.edu.cn+86 13755087574

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026